The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 988-994

  Martinez Cajas, Jorge L ^a   Wainberg, Mark A ^b   Oliveira, Maureen ^b   Asahchop, Eugene L ^b   Doualla Bell, Florence ^b   Lisovsky, Irene ^b   Moisi, Daniela ^b   Mendelson, Ella ^c   Grossman, Zehava ^d   Brenner, Bluma G ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MINISTRY OF HEALTH   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiretroviral drugs; Genetic diversity; HIV; Mutations; Non B subtypes

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; NELFINAVIR; SAQUINAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CODON; DRUG TREATMENT FAILURE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; TISSUE CULTURE; UMBILICAL CORD BLOOD;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; LOPINAVIR; NELFINAVIR; OLIGOPEPTIDES; POLYMORPHISM, GENETIC; PYRIDINES; VIRUS CULTIVATION;

EID: 84858674882     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr582     Document Type: Article

References (29)

1. Hemelaar J, Gouws E, Ghys PD et al. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25: 679-89.
2. Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis 2011; 11: 45-56.
3. Hamers RL, Wallis CL, Kityo C et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11: 750-9.
4. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003; 5: 25-35.
5. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365: 637-46.
6. Tejerina F, Lopez Bernaldo de Quiros JC. Protease inhibitors as preferred initial regimen for antiretroviral-naive HIV patients. AIDS Rev 2011; 13: 227-33.
7. Martinez-Cajas JL, Pant-Pai N, Klein MB et al. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008; 10: 212-23.
8. Martinez-Cajas JL, Pai NP, Klein MB et al. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009; 12: 11.
9. Abecasis AB, Deforche K, Snoeck J et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005; 19: 1799-806.
10. Ariyoshi K, Matsuda M, Miura H et al. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003; 33: 336-42.
11. Brenner B, Turner D, Oliveira M et al. AV106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17: F1-5.
12. Brenner BG, Oliveira M, Doualla-Bell F et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20: F9-13.
13. Grossman Z, Paxinos EE, Averbuch D et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48: 2159-65.
14. Poonpiriya V, Sungkanuparph S, Leechanachai P et al. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand. J Virol Methods 2008; 151: 79-86.
15. Snoeck J, Kantor R, Shafer RW et al. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother 2006; 50: 694-701.
16. Vergne L, Snoeck J, Aghokeng A et al. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006; 46: 53-62.
17. Vermeiren H, Van Craenenbroeck E, Alen P et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 2007; 145: 47-55.
18. Oliveira M, Brenner BG, Wainberg MA. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol 2009; 485: 427-33.
19. Loemba H, Brenner B, Parniak MA et al. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46: 2087-94.
20. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18: 156-63.
21. Rhee SY, Taylor J, Fessel WJ et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 2010; 54: 4253-61.
22. De Meyer S, Lathouwers E, Dierynck I et al. Characterization of virologic failure patients on darunavir/ritonavir in treatmentexperienced patients. AIDS 2009; 23: 1829-40.
23. Pozniak A, Opravil M, Beatty G et al. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2. AIDS Res Hum Retroviruses 2008; 24: 1275-80.
24. Lisovsky I, Schader SM, Martinez-Cajas JL et al. HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrob Agents Chemother 2010; 54: 2878-85.
25. Colonno R, Rose R, McLaren C et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189: 1802-10.
26. Gong YF, Robinson BS, Rose RE et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44: 2319-26.
27. Calazans A, Brindeiro R, Brindeiro P et al. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. J Infect Dis 2005; 191: 1961-70.
28. Chaix ML, Rouet F, Kouakoussui KA et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J 2005; 24: 1072-6.
29. Martin P, Vickrey JF, Proteasa G et al. "Wide-open" 1.3Å structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 2005; 13: 1887-95.